Acadia Pharmaceuticals EVP sells $48,534 in stock

SAN DIEGO, CA - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) has reported a recent transaction involving its executive vice president and chief financial officer, Mark C. Schneyer. According to the latest filings, Schneyer sold shares of the company's common stock with a total value of $48,534.

The sale occurred on April 8, 2024, and involved a total of 2,716 shares at a weighted average price of $17.87. The transactions were made in multiple sales with prices ranging from $17.7338 to $17.87. The sales were part of a prearranged plan to cover withholding taxes and tax-related items associated with the vesting of restricted stock units, as indicated in the footnotes of the filing.

In addition to the sale, Schneyer also acquired 5,275 shares of common stock on April 5, 2024, through the exercise of options. These transactions were related to restricted stock units that vest in four equal annual installments, beginning April 5, 2023.

Following these transactions, Schneyer's direct ownership in the company stands at 28,742 shares of common stock. The disclosure of these transactions provides investors with insight into the financial activities of Acadia Pharmaceuticals' executives and may be of interest to current and potential shareholders.

Acadia Pharmaceuticals, headquartered in San Diego, California, specializes in the development and commercialization of pharmaceutical products aimed at treating central nervous system disorders.

Amid the executive financial maneuvers, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) presents a mixed financial canvas, according to recent data from InvestingPro. The company holds a market capitalization of approximately $2.99 billion, reflecting its standing in the biopharmaceutical industry. Notably, the company's revenue has shown robust growth over the last year, with a 40.45% increase in the last twelve months as of Q4 2023, and an even more impressive quarterly jump of 69.27% in Q4 2023.

However, the company's P/E ratio stands at a negative -46.4, highlighting the market's concerns over profitability, a sentiment echoed by the company's negative operating income margin of -10.1%. While the current Price / Book ratio is at 6.93, indicating a premium valuation, one of the InvestingPro Tips suggests that the stock is trading near its 52-week low, which could be a signal for value-oriented investors.

For those considering Acadia Pharmaceuticals as an investment, it's worth noting that the company does not pay a dividend, which could influence the investment strategies of income-focused investors. Moreover, while the stock has experienced a significant decline over the last three months, with a 41.94% drop in price total return, another InvestingPro Tip indicates that the stock is currently in oversold territory according to the RSI, potentially presenting a buying opportunity for contrarian investors.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

To gain a deeper understanding of Acadia Pharmaceuticals and access additional insights, investors can explore more InvestingPro Tips at https://www.investing.com/pro/ACAD. There are 11 tips in total available, providing a broad perspective on the company's financial health and stock performance. For those interested in a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24 to receive an additional 10% off.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.